Dana-Farber Cancer Institute /ID# 219162 — Boston, Massachusetts

Dana-Farber Cancer Institute /ID# 219162 is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Dana-Farber Cancer Institute /ID# 219162 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Myelodysplastic Syndrome (MDS).

Sponsors: AbbVie.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber Cancer Institute /ID# 219162?

Dana-Farber Cancer Institute /ID# 219162 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber Cancer Institute /ID# 219162 conducted?

Dana-Farber Cancer Institute /ID# 219162 has 1 clinical trials on record, with 1 currently active. Their work covers Myelodysplastic Syndrome (MDS).

Is Dana-Farber Cancer Institute /ID# 219162 accredited by Crixeo Health?

Dana-Farber Cancer Institute /ID# 219162 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana-Farber Cancer Institute /ID# 219162?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.